Bromodomain inhibitors a decade later: a promise unfulfilled?

Advanced Search

Monica M Mita, Alain C Mita

Author Information

Monica M Mita: The Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Alain C Mita: The Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. alain.mita@cshs.org. ORCID

PMID: 32989227 DOI: 10.1038/s41416-020-01079-x

Over the last decade, bromodomain inhibitors have emerged as a promising class of anticancer drugs. However, the clinical progress of these agents has faced significant obstacles, which precluded their regulatory approval. This editorial will review the challenges and opportunities associated with the development of bromodomain inhibitors.

Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011). [DOI: 10.1016/j.cell.2011.02.013]
Tamkun, J. W., Deuring, R., Scott, M. P., Kissinger, M., Pattatucci, A. M., Kaufman, T. C. et al. Brahma: a regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2/SWI2. Cell 68, 561–572 (1992). [DOI: 10.1016/0092-8674(92)90191-E]
Ameratunga, M., Brana, I., Bono, P., Postel-Vinay, S., Plummer, E., Aspegren, J. et al. First-in-human Phase 1 open label study of BET inhibitor ODM-207 in patients with selected solid tumours. Br. J. Cancer https://doi.org/10.1038/s41416-020-01077-z (2020).
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O. et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010). [DOI: 10.1038/nature09504]
Pérez-Salvia, M. & Esteller, M. Bromodomain inhibitors and cancer therapy: from structures to applications. Epigenetics 12, 323–339 (2017). [DOI: 10.1080/15592294.2016.1265710]
Alqahtani, A., Choucair, K., Ashraf, M., Hammouda, D. M., Alloghbi, A., Khan, T. et al. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci. OA 5, FSO372 (2019). [DOI: 10.4155/fsoa-2018-0115]
Jain, A. K. & Barton, M. C. Bromodomain histone readers and cancer. J. Mol. Biol. 429, 2003–2010 (2017). [DOI: 10.1016/j.jmb.2016.11.020]
Zhu, H., Bengsch, F., Svoronos, N., Rutkowski, M. R., Bitler, B. G., Allegrezza, M. J. et al. BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression. Cell Rep. 16, 2829–2837 (2016). [DOI: 10.1016/j.celrep.2016.08.032]
Jing, X., Shao, S., Zhang, Y., Luo, A., Zhao, L., Zhang, L. et al. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer. Exp. Cell Res. 392, 112034 (2020). [DOI: 10.1016/j.yexcr.2020.112034]
Yang, L., Zhang, Y., Shan, W., Hu, Z., Yuan, J., Pi, J. et al. Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci. Transl. Med. 9, eaal1645 (2017). [DOI: 10.1126/scitranslmed.aal1645]
Karakashev, S., Zhu, H., Yokoyama, Y., Zhao, B., Fatkhutdinov, N., Kossenkov, A. V. et al. BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer. Cell Rep. 21, 3398–3405 (2017). [DOI: 10.1016/j.celrep.2017.11.095]

Antineoplastic Agents

Humans

Neoplasms

Protein Domains

Antineoplastic Agents

Editorial Comment

OpenLB
Open Library of Bioscience